Liu, Wang-Da
Hou, Hsin-An
Li, Ko-Jen
Qin, Albert
Tsai, Chan-Yen
Sheng, Wang-Huei
Clinical trials referenced in this document:
Documents that mention this clinical trial
Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities
https://doi.org/10.1007/s12325-023-02715-7
Funding for this research was provided by:
PharmaEssentia Corporation
Article History
Received: 12 September 2023
Accepted: 17 October 2023
First Online: 27 November 2023
Declarations
:
: Wang-Huei Sheng, Wang-Da Liu, and Ko-Jen Li declare no conflict of interest. Hsin-An Hou declares the honorarium, travel and research support from PharmaEssentia Corporation. Albert Qin and Chan-Yen Tsai work for PharmaEssentia Corporation.
: The study is approved by the institutional review board of NTUH IRB (approval number 202302136MIPD) and follows the principles of the Declaration of Helsinki for all human experimental investigations. Informed consent will be obtained from all participating patients.